Active Recombinant Human CLDN3 Full Length Full Length Transmembrane protein, His-tagged(VLPs)

• Cat.No.: CLDN3-10H
• Product Overview: Recombinant Human CLDN3 Full Length protein(O15551)(1-220aa)(VLPs), fused with His tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: His
• Form: Lyophilized from a 0.2 μm filtered PBS, 6% Trehalose, pH 7.4
• Bio-activity: Measured by its binding ability in a functional ELISA. Immobilized Human CLDN3 at 10 μg/mL can bind Anti-CLDN3 recombinant antibody, the EC50 is 23.62-34.37 ng/mL.VLPs is negative control.
• Molecular Mass: 24.7 kDa
• Protein Length: 1-220aa
• AA Sequence: MSMGLEITGTALAVLGWLGTIVCCA LPMWRVSAFIGSNIITSQNIWEGLW MNCVVQSTGQMQCKVYDSLLALPQD LQAARALIVVAILLAAFGLLVALVG AQCTNCVQDDTAKAKITIVAGVLFL LAALLTLVPVSWSANTIIRDFYNPV VPEAQKREMGAGLYVGWAAAALQLL GGALLCCSCPPREKKYTATKVVYSA PRSTGPGASLGTGYDRKDYV
• Endotoxin: Less than 1.0 EU/ug as determined by LAL method.
• Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
• Reconstitution: Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%.

Gene Information

• Gene Name: CLDN3 claudin 3 [ Homo sapiens ]
• Official Symbol: CLDN3
• Synonyms: CLDN3; claudin 3; C7orf1, CPETR2; claudin-3; Clostridium perfringens enterotoxin receptor 2; CPE R2; CPE receptor 2; HRVP1; RVP1; ventral prostate.1 like protein; CPE-R 2; CPE-receptor 2; ventral prostate.1-like protein; ventral prostate.1 protein homolog; C7orf1; CPE-R2; CPETR2
• Gene ID: 1365
• mRNA Refseq: NM_001306
• Protein Refseq: NP_001297
• MIM: 602910
• UniProt ID: O15551

Reviews

04/24/2019

The manufacturer's deep understanding of the protein and its applications enables them to promptly and effectively address any issues that may arise during my trials.

06/30/2018

It minimizes the risk of protein degradation and maximizes the effectiveness of the protein in various applications, such as cell signaling pathways or metabolic studies.

12/12/2017

This stability is particularly advantageous for long-term studies or experiments involving extended incubation periods.

Q&As

Is CLDN3 a potential target for drug delivery to specific tissues?

Researchers are exploring the use of CLDN3 as a target for drug delivery systems, aiming to enhance the specificity of drug delivery to tissues expressing high levels of CLDN3.

How does CLDN3 impact the permeability of the intestinal epithelium?

CLDN3 is involved in the tight junctions of intestinal epithelial cells, influencing the permeability of the intestinal barrier and playing a role in conditions like IBD.

In which other diseases or conditions is CLDN3 being investigated?

CLDN3 is under investigation in various conditions, including infectious diseases, where its role in tight junctions may have implications for host-pathogen interactions.

Can CLDN3 be involved in inflammatory bowel diseases (IBD)?

Yes, CLDN3 is implicated in the pathogenesis of inflammatory bowel diseases, and its expression levels are being studied as potential markers for disease severity.

How is CLDN3 linked to neurodegenerative diseases?

Altered expression of CLDN3 in the blood-brain barrier is associated with certain neurodegenerative diseases, making it a subject of interest for researchers studying these conditions.